Cargando…
[(18)F]ML-10 PET imaging fails to assess early response to neoadjuvant chemotherapy in a preclinical model of triple negative breast cancer
PURPOSE: Pathological complete response to the neoadjuvant therapy (NAT) for triple negative breast cancer (TNBC) is predictive of prolonged patient survival. Methods for early evaluation of NAT efficiency are still needed, in order to rapidly adjust the therapeutic strategy in case of initial non-r...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944726/ https://www.ncbi.nlm.nih.gov/pubmed/31907640 http://dx.doi.org/10.1186/s13550-019-0587-5 |
_version_ | 1783485067156258816 |
---|---|
author | Jouberton, Elodie Schmitt, Sébastien Chautard, Emmanuel Maisonial-Besset, Aurélie Roy, Marie Radosevic-Robin, Nina Chezal, Jean-Michel Miot-Noirault, Elisabeth Bouvet, Yann Cachin, Florent |
author_facet | Jouberton, Elodie Schmitt, Sébastien Chautard, Emmanuel Maisonial-Besset, Aurélie Roy, Marie Radosevic-Robin, Nina Chezal, Jean-Michel Miot-Noirault, Elisabeth Bouvet, Yann Cachin, Florent |
author_sort | Jouberton, Elodie |
collection | PubMed |
description | PURPOSE: Pathological complete response to the neoadjuvant therapy (NAT) for triple negative breast cancer (TNBC) is predictive of prolonged patient survival. Methods for early evaluation of NAT efficiency are still needed, in order to rapidly adjust the therapeutic strategy in case of initial non-response. One option for this is molecular imaging of apoptosis induced by chemotherapy. Therefore, we investigated the capacity of [(18)F]ML-10 PET imaging, an apoptosis radiotracer, to detect tumor cell apoptosis and early predict the therapeutic response of human TNBC. RESULTS: Initially, the induction of apoptosis by different therapies was quantified. We confirmed, in vitro, that paclitaxel or epirubicin, the fundamental cytotoxic drugs for breast cancer, induce apoptosis in TNBC cell lines. Exposure of TNBC models MDA-MB-231 and MDA-MB-468 to these drugs induced a significant increase (p < 0.01) of the apoptotic hallmarks: DNA fragmentation, membrane phospholipid scrambling, and PARP activation. Secondarily, apoptotic fraction was compared to the intracellular accumulation of the radiotracer. [(18)F]ML-10 accumulated in the apoptotic cells after 72 h of treatment by paclitaxel in vitro; this accumulation positively correlated with the apoptotic fraction. In vivo, [(18)F]ML-10 was rapidly cleared from the nontarget organs and mainly eliminated by the kidneys. Comparison of the in vivo [(18)F]FDG, [(18)F]FMISO, and [(18)F]ML-10 uptakes revealed that the tumor accumulation of [(18)F]ML-10 was directly related to the tumor hypoxia level. Finally, after the in vivo treatment of TNBC murine xenografts by paclitaxel, apoptosis was well induced, as demonstrated by the cleaved caspase-3 levels; however, no significant increase of [(18)F]ML-10 accumulation in the tumors was observed, either on day 3 or day 6 after the end of the treatment. CONCLUSIONS: These results highlighted that PET imaging using [(18)F]ML-10 allows the visualization of apoptotic cells in TNBC models. Nevertheless, the increase of the chemotherapy-induced apoptotic response when using paclitaxel could not be assessed using this radiotracer in our mouse model. |
format | Online Article Text |
id | pubmed-6944726 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-69447262020-01-23 [(18)F]ML-10 PET imaging fails to assess early response to neoadjuvant chemotherapy in a preclinical model of triple negative breast cancer Jouberton, Elodie Schmitt, Sébastien Chautard, Emmanuel Maisonial-Besset, Aurélie Roy, Marie Radosevic-Robin, Nina Chezal, Jean-Michel Miot-Noirault, Elisabeth Bouvet, Yann Cachin, Florent EJNMMI Res Original Research PURPOSE: Pathological complete response to the neoadjuvant therapy (NAT) for triple negative breast cancer (TNBC) is predictive of prolonged patient survival. Methods for early evaluation of NAT efficiency are still needed, in order to rapidly adjust the therapeutic strategy in case of initial non-response. One option for this is molecular imaging of apoptosis induced by chemotherapy. Therefore, we investigated the capacity of [(18)F]ML-10 PET imaging, an apoptosis radiotracer, to detect tumor cell apoptosis and early predict the therapeutic response of human TNBC. RESULTS: Initially, the induction of apoptosis by different therapies was quantified. We confirmed, in vitro, that paclitaxel or epirubicin, the fundamental cytotoxic drugs for breast cancer, induce apoptosis in TNBC cell lines. Exposure of TNBC models MDA-MB-231 and MDA-MB-468 to these drugs induced a significant increase (p < 0.01) of the apoptotic hallmarks: DNA fragmentation, membrane phospholipid scrambling, and PARP activation. Secondarily, apoptotic fraction was compared to the intracellular accumulation of the radiotracer. [(18)F]ML-10 accumulated in the apoptotic cells after 72 h of treatment by paclitaxel in vitro; this accumulation positively correlated with the apoptotic fraction. In vivo, [(18)F]ML-10 was rapidly cleared from the nontarget organs and mainly eliminated by the kidneys. Comparison of the in vivo [(18)F]FDG, [(18)F]FMISO, and [(18)F]ML-10 uptakes revealed that the tumor accumulation of [(18)F]ML-10 was directly related to the tumor hypoxia level. Finally, after the in vivo treatment of TNBC murine xenografts by paclitaxel, apoptosis was well induced, as demonstrated by the cleaved caspase-3 levels; however, no significant increase of [(18)F]ML-10 accumulation in the tumors was observed, either on day 3 or day 6 after the end of the treatment. CONCLUSIONS: These results highlighted that PET imaging using [(18)F]ML-10 allows the visualization of apoptotic cells in TNBC models. Nevertheless, the increase of the chemotherapy-induced apoptotic response when using paclitaxel could not be assessed using this radiotracer in our mouse model. Springer Berlin Heidelberg 2020-01-06 /pmc/articles/PMC6944726/ /pubmed/31907640 http://dx.doi.org/10.1186/s13550-019-0587-5 Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Research Jouberton, Elodie Schmitt, Sébastien Chautard, Emmanuel Maisonial-Besset, Aurélie Roy, Marie Radosevic-Robin, Nina Chezal, Jean-Michel Miot-Noirault, Elisabeth Bouvet, Yann Cachin, Florent [(18)F]ML-10 PET imaging fails to assess early response to neoadjuvant chemotherapy in a preclinical model of triple negative breast cancer |
title | [(18)F]ML-10 PET imaging fails to assess early response to neoadjuvant chemotherapy in a preclinical model of triple negative breast cancer |
title_full | [(18)F]ML-10 PET imaging fails to assess early response to neoadjuvant chemotherapy in a preclinical model of triple negative breast cancer |
title_fullStr | [(18)F]ML-10 PET imaging fails to assess early response to neoadjuvant chemotherapy in a preclinical model of triple negative breast cancer |
title_full_unstemmed | [(18)F]ML-10 PET imaging fails to assess early response to neoadjuvant chemotherapy in a preclinical model of triple negative breast cancer |
title_short | [(18)F]ML-10 PET imaging fails to assess early response to neoadjuvant chemotherapy in a preclinical model of triple negative breast cancer |
title_sort | [(18)f]ml-10 pet imaging fails to assess early response to neoadjuvant chemotherapy in a preclinical model of triple negative breast cancer |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944726/ https://www.ncbi.nlm.nih.gov/pubmed/31907640 http://dx.doi.org/10.1186/s13550-019-0587-5 |
work_keys_str_mv | AT joubertonelodie 18fml10petimagingfailstoassessearlyresponsetoneoadjuvantchemotherapyinapreclinicalmodeloftriplenegativebreastcancer AT schmittsebastien 18fml10petimagingfailstoassessearlyresponsetoneoadjuvantchemotherapyinapreclinicalmodeloftriplenegativebreastcancer AT chautardemmanuel 18fml10petimagingfailstoassessearlyresponsetoneoadjuvantchemotherapyinapreclinicalmodeloftriplenegativebreastcancer AT maisonialbessetaurelie 18fml10petimagingfailstoassessearlyresponsetoneoadjuvantchemotherapyinapreclinicalmodeloftriplenegativebreastcancer AT roymarie 18fml10petimagingfailstoassessearlyresponsetoneoadjuvantchemotherapyinapreclinicalmodeloftriplenegativebreastcancer AT radosevicrobinnina 18fml10petimagingfailstoassessearlyresponsetoneoadjuvantchemotherapyinapreclinicalmodeloftriplenegativebreastcancer AT chezaljeanmichel 18fml10petimagingfailstoassessearlyresponsetoneoadjuvantchemotherapyinapreclinicalmodeloftriplenegativebreastcancer AT miotnoiraultelisabeth 18fml10petimagingfailstoassessearlyresponsetoneoadjuvantchemotherapyinapreclinicalmodeloftriplenegativebreastcancer AT bouvetyann 18fml10petimagingfailstoassessearlyresponsetoneoadjuvantchemotherapyinapreclinicalmodeloftriplenegativebreastcancer AT cachinflorent 18fml10petimagingfailstoassessearlyresponsetoneoadjuvantchemotherapyinapreclinicalmodeloftriplenegativebreastcancer |